SlideShare a Scribd company logo
1 of 121
MANAGEMENT OF DYSLPIDEMIA IN FAMILY PRACTICE D  R  .  G  .  C  .  D  H  A  R
EARLY DETECTION BY WHOM?
Family Physician As a member of the patient’s family
 
 
 
 
 
 
 
 
P  H  Y  S  I  C  A  L  I  N  A  C  T  I  V  I  T  Y H  I  G  H  C  A  L  O  R  I  E  D  I  E  T
 
KEY WORDS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
What is dyslipidemia? ,[object Object],[object Object],[object Object],[object Object],[object Object]
Fats, Lipids & Lipoproteins in Clinical Lipidology
What is Lipid? ,[object Object],[object Object]
DIETARY LIPID (major source of energy) COMPOSED OF ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Dietary fat mainly composed of Triglyceride
DIETARY STEROLS 0.1-2% of total dietary fat.
LIPID METABOLISM Triglyceride ,[object Object],[object Object],[object Object],[object Object]
 
LIPIDS- lipophilic   LIPOPROTEINS-  Hydrophilic
 
Lipoprotein particle ,[object Object],[object Object]
Four main types of lipoproteins ,[object Object],[object Object]
Four main types of lipoproteins ,[object Object],[object Object]
Contents of lipoprotein particles
Patient Visit-1 ,[object Object],[object Object],[object Object],[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-1 cont’d (Physical examination) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object],[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object],[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-1 cont’d ,[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object],[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object],[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object]
DYSLIPIDEMIA RISK ASSESSMENT ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Framingham Risk Score ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
To estimate 10 year risk of death from CAD or non-fatal Myocardial infarction
Risk categories: ,[object Object],[object Object]
Risk categories: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
What is the risk of our patient? ,[object Object],[object Object]
Visit-1 cont’d ,[object Object],[object Object],[object Object],[object Object]
Visit-2 (after 3 months) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-2 cont’d ,[object Object],[object Object]
Visit-2 cont’d ,[object Object],[object Object],[object Object],[object Object]
Visit-2 cont’d ,[object Object],[object Object],[object Object]
Visit-2 cont’d (explanation) ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
DO REMEMBER! ,[object Object]
Drugs used in lipid lowering therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-2 cont’d ,[object Object],[object Object],[object Object],[object Object]
Visit-2 cont’d ,[object Object],[object Object],[object Object]
Visit-2 cont’d (prescribe a statin-explanation) ,[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-2 cont’d ,[object Object]
Do not forget about statin side effects! ,[object Object],[object Object],[object Object]
Do not forget about statin side effects! ,[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-3  (after 6 months) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-3 cont’d ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-3 Cont’d ,[object Object],[object Object],[object Object]
Visit-3 Cont’d ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-3 cont’d (Fibrate or nicotinic acid) ,[object Object],[object Object]
Visit-3 con’d ,[object Object],[object Object],[object Object],[object Object]
Why nicotinic acid? ,[object Object],[object Object],[object Object],[object Object]
Visit-4 After 9 months ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Hyperlipidemia  (Secondary causes) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Dyslipidemia (Genetic causes) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Visit-1 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Skin: Yellow patches under his eyes (Xanthoma)
Skin: Yellow patches on the palmar surface of hands (Xanthoma)
What is the most likely Dx? ,[object Object],[object Object]
Isolated hypertriglyceridemia? NO ,[object Object],[object Object]
 
Most likely diagnosis is Familial Hypercholesterolemia. ,[object Object],[object Object],[object Object]
What is the initial screening test required for this patient? ,[object Object],[object Object],[object Object],[object Object]
Our patient’s fasting lipid profile ,[object Object],[object Object],[object Object]
Calculate LDL level by Friedewald Equation
Friedewald Equation ,[object Object],[object Object],[object Object],[object Object],[object Object]
For this patient 355 – 40 – (0.20X100) = 295 LDL-C = 295mg/dl
According to Fredrickson Classification Which type of dyslipidemia is it?
Familial hypercholesterolemia ,[object Object],[object Object]
What is our next step? ,[object Object],[object Object],[object Object]
Patient was started atorvastatin 40mg/day. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
He is not in his target with high dose of statin. ,[object Object],[object Object],[object Object]
After 6 months ,[object Object],[object Object],[object Object],[object Object],[object Object]
What is our next step? ? ? ? ?
LIPID APHERESIS ,[object Object]
What is lipid apheresis? ,[object Object],[object Object],[object Object],[object Object],[object Object]
C  H  I  L  D  H  O  O  D D  Y  S  L  I  P  I  D  E  M  I  A
Ref: AMERICAN ACADEMY OF PEDIATRICS PEDIATRICS Vol. 122 No. 1 July 2008, pp. 198-208 (doi:10.1542/peds.2008-1349)
Cholesterol screening in the form of  LIPID PROFILE  is recommended for: ,[object Object],[object Object],[object Object]
If values are normal, testing should be repeated in 3-5 years. ,[object Object],[object Object],[object Object]
For the children of 8 years of age or above with high LDL-C: ,[object Object],[object Object],[object Object],[object Object],[object Object]
Pharmacological intervention with primary goal <160mg/dl and gradually up to <110mg/dl
LIPID LOWERING DRUGS FOR CHILDREN ,[object Object],[object Object],[object Object]
LDL-C OR LDL-P? ,[object Object]
 
 
 
 
 
NOT LDL-C BUT LDL-P
Each of the atherogenic particles ,[object Object]
NMR LipoProfile ,[object Object]
DIABETIC DYSLIPIDEMIA ,[object Object]
DIABETIC DYSLIPIDEMIA ,[object Object],[object Object],[object Object],[object Object]
DIABETIC DYSLIPIDEMIA ,[object Object],[object Object],[object Object]
PRACTICE TIPS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
PRACTICE TIPS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
PRACTICE TIPS ,[object Object],[object Object],[object Object],[object Object]
PRACTICE TIPS ,[object Object],[object Object],[object Object],[object Object]
Lipid Profile analysis in risky patients ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
SOCRATES (469 BC - 399 BC) ,[object Object],[object Object],[object Object],[object Object],[object Object]
 

More Related Content

What's hot

Ueda2015 d.dyslipidemia dr.khaled hadidy
Ueda2015 d.dyslipidemia dr.khaled hadidyUeda2015 d.dyslipidemia dr.khaled hadidy
Ueda2015 d.dyslipidemia dr.khaled hadidy
ueda2015
 

What's hot (20)

Dyslipidemia diagnosis and management
Dyslipidemia  diagnosis and managementDyslipidemia  diagnosis and management
Dyslipidemia diagnosis and management
 
Diabetic Dyslipidemia Slide Share
Diabetic  Dyslipidemia Slide ShareDiabetic  Dyslipidemia Slide Share
Diabetic Dyslipidemia Slide Share
 
Hypertensive Dyslipidaemics
Hypertensive DyslipidaemicsHypertensive Dyslipidaemics
Hypertensive Dyslipidaemics
 
Dyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approach
 
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CADTHE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
 
Diabetic dyslipidemia
Diabetic dyslipidemiaDiabetic dyslipidemia
Diabetic dyslipidemia
 
Dyslipidemia guideline review : the transatlantic differences
Dyslipidemia guideline review : the transatlantic differencesDyslipidemia guideline review : the transatlantic differences
Dyslipidemia guideline review : the transatlantic differences
 
Management of dyslipidemia
Management of dyslipidemiaManagement of dyslipidemia
Management of dyslipidemia
 
Dyslipidemia protocol
Dyslipidemia protocolDyslipidemia protocol
Dyslipidemia protocol
 
Dyslipidemia Guidelines 2016
Dyslipidemia Guidelines 2016Dyslipidemia Guidelines 2016
Dyslipidemia Guidelines 2016
 
P001-Management of Dyslipidemia
P001-Management of DyslipidemiaP001-Management of Dyslipidemia
P001-Management of Dyslipidemia
 
The ESC/EAS Guidelines
The ESC/EAS GuidelinesThe ESC/EAS Guidelines
The ESC/EAS Guidelines
 
Review of Lipid Guidelines 2011 to 2017
Review of Lipid Guidelines 2011 to 2017Review of Lipid Guidelines 2011 to 2017
Review of Lipid Guidelines 2011 to 2017
 
Ueda2015 d.dyslipidemia dr.khaled hadidy
Ueda2015 d.dyslipidemia dr.khaled hadidyUeda2015 d.dyslipidemia dr.khaled hadidy
Ueda2015 d.dyslipidemia dr.khaled hadidy
 
Current management of dyslipidemia final
Current management of dyslipidemia finalCurrent management of dyslipidemia final
Current management of dyslipidemia final
 
Dyslipidemia 2016
Dyslipidemia 2016Dyslipidemia 2016
Dyslipidemia 2016
 
Dyslipdemia Guidelines Head to Head
Dyslipdemia Guidelines Head to HeadDyslipdemia Guidelines Head to Head
Dyslipdemia Guidelines Head to Head
 
Diabetic dyslipidemia and Saroglitazar
Diabetic dyslipidemia and SaroglitazarDiabetic dyslipidemia and Saroglitazar
Diabetic dyslipidemia and Saroglitazar
 
DYSLIPIDEMIA GUIDELINES
DYSLIPIDEMIA GUIDELINESDYSLIPIDEMIA GUIDELINES
DYSLIPIDEMIA GUIDELINES
 
Dyslipidemia & ayurveda
Dyslipidemia & ayurvedaDyslipidemia & ayurveda
Dyslipidemia & ayurveda
 

Similar to Dyslpidemia Cme Com 25 May09

Ped488 dyslipidemia s 11
Ped488 dyslipidemia s 11Ped488 dyslipidemia s 11
Ped488 dyslipidemia s 11
mjpol
 

Similar to Dyslpidemia Cme Com 25 May09 (20)

Lipid Guidelines - Dr. Ajay Kantharia
Lipid Guidelines - Dr. Ajay KanthariaLipid Guidelines - Dr. Ajay Kantharia
Lipid Guidelines - Dr. Ajay Kantharia
 
Dyslipidemia
DyslipidemiaDyslipidemia
Dyslipidemia
 
Hyperlipidemia
Hyperlipidemia Hyperlipidemia
Hyperlipidemia
 
Anti dyslipidemic agents
Anti dyslipidemic agentsAnti dyslipidemic agents
Anti dyslipidemic agents
 
Hyperlipidaemia
HyperlipidaemiaHyperlipidaemia
Hyperlipidaemia
 
Complications of abnormal lipid levels
Complications of abnormal lipid levelsComplications of abnormal lipid levels
Complications of abnormal lipid levels
 
Cardiometabolic syndrome
Cardiometabolic syndromeCardiometabolic syndrome
Cardiometabolic syndrome
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
Dyslipidaemia part one.pdf
Dyslipidaemia part one.pdfDyslipidaemia part one.pdf
Dyslipidaemia part one.pdf
 
Diabetic dyslipidemia
Diabetic dyslipidemiaDiabetic dyslipidemia
Diabetic dyslipidemia
 
2. prof. bambang irawan cv assessment in met s and t2dm [compatibility mode]
2. prof. bambang irawan cv assessment in met s and t2dm [compatibility mode]2. prof. bambang irawan cv assessment in met s and t2dm [compatibility mode]
2. prof. bambang irawan cv assessment in met s and t2dm [compatibility mode]
 
Lipid profile test ppt
Lipid profile test pptLipid profile test ppt
Lipid profile test ppt
 
Shelly hyperlipidemia
Shelly hyperlipidemiaShelly hyperlipidemia
Shelly hyperlipidemia
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
metabolic syndrome by dr amber.pptx
metabolic syndrome by dr amber.pptxmetabolic syndrome by dr amber.pptx
metabolic syndrome by dr amber.pptx
 
Metabolic syndrome toufiqur rahman
Metabolic syndrome toufiqur rahmanMetabolic syndrome toufiqur rahman
Metabolic syndrome toufiqur rahman
 
Ped488 dyslipidemia s 11
Ped488 dyslipidemia s 11Ped488 dyslipidemia s 11
Ped488 dyslipidemia s 11
 
Dyslipidemia.docx
Dyslipidemia.docxDyslipidemia.docx
Dyslipidemia.docx
 
Diabetic Dyslipidemia- Dr Shahjada Selim
Diabetic Dyslipidemia- Dr Shahjada SelimDiabetic Dyslipidemia- Dr Shahjada Selim
Diabetic Dyslipidemia- Dr Shahjada Selim
 
Hyperlipidemia.pptx
Hyperlipidemia.pptxHyperlipidemia.pptx
Hyperlipidemia.pptx
 

More from Gauranga Dhar (7)

2014 november-nem
2014 november-nem2014 november-nem
2014 november-nem
 
Bafp Free 2009
Bafp Free 2009Bafp Free 2009
Bafp Free 2009
 
Nem Dec 09
Nem Dec 09Nem Dec 09
Nem Dec 09
 
Nem Oct 09
Nem Oct 09Nem Oct 09
Nem Oct 09
 
Nem Nov 08
Nem Nov 08Nem Nov 08
Nem Nov 08
 
Nem Oct 08
Nem Oct 08Nem Oct 08
Nem Oct 08
 
Management Of Obesity In Family Practice Cme 30 May08
Management Of Obesity In Family Practice Cme 30 May08Management Of Obesity In Family Practice Cme 30 May08
Management Of Obesity In Family Practice Cme 30 May08
 

Dyslpidemia Cme Com 25 May09